This is the public knowledge portal for the Accelerating Medicine Partnership for Alzheimer's Disease (NIA-AMP AD) Target Discovery and Preclinical Validation Project. The AMP-AD program is a precompetitive partnership between government, industry and non-profit foundations focused on the discovery of novel, clinically relevant therapeutic targets and the development of biomarkers to aid the validation of existing therapeutic targets.
The goal of the Target Discovery and Preclinical Validation project is to shorten the time between discovery of potential drug targets to development of new drugs for the treatment and prevention of Alzheimer’s disease, by integrating the analysis of large scale molecular data from human brain samples with network modeling approaches and experimental validation, and by enabling rapid and broad sharing of data and analytical tools. The project is a consortium of 4 NIA supported multi-institutional, multidisciplinary cooperative agreement grants. The grant awardees are expected to engage in broad sharing of biological data and analytical methodology prior to publication. This portal will host data and knowledge generated by the members of the consortium. Content in this portal will be updated quarterly to incorporate emerging resources.
The goal of the Target Discovery and Preclinical Validation project is to shorten the time between discovery of potential drug targets to development of new drugs for the treatment and prevention of Alzheimer’s disease, by integrating the analysis of large scale molecular data from human brain samples with network modeling approaches and experimental validation, and by enabling rapid and broad sharing of data and analytical tools. The project is a consortium of 4 NIA supported multi-institutional, multidisciplinary cooperative agreement grants. The grant awardees are expected to engage in broad sharing of biological data and analytical methodology prior to publication. This portal will host data and knowledge generated by the members of the consortium. Content in this portal will be updated quarterly to incorporate emerging resources.
No comments:
Post a Comment